Search results
Targeting CXCR4 impaired T regulatory function through PTEN in renal cancer patients - British...
Nature· 1 day agoTregs trafficking is controlled by CXCR4. In Renal Cell Carcinoma (RCC), the effect of the new CXCR4 antagonist, R54, was explored in ...
Afinitor interactions: Other medications, alcohol, and more
Medical News Today· 2 days agoAfinitor has interactions with some other drugs and certain supplements. Before you start treatment...
Moderna plants new solid tumor trials for cancer vaccine, weeds PD-1 work after review
FierceBiotech· 3 days agoModerna detailed plans for its individual neoantigen cancer vaccine in a first-quarter earnings...
Cameron Mathison Shares Heartfelt Post as His Daughter Leila Heads to Prom: ‘Always on My Mind and...
People Magazine· 6 days agoCameron Mathison shared a tender moment with his daughter Leila as she prepared to head off to her...
Exelixis (EXEL) Q1 Earnings Miss, Cabometyx Sales Fall Short
Zacks via Yahoo Finance· 4 days agoCabometyx (cabozantinib) generated revenues of $376.4 million, which missed the Zacks Consensus...
Moderna (MRNA) Q1 Earnings Beat Estimates, Revenues Down Y/Y
Zacks via Yahoo Finance· 3 days agoModerna/Merck also started two separate mid-stage studies in renal cell carcinoma and...
Merck & Co., Inc. (NYSE:MRK) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 5 days agoMerck & Co., Inc. (NYSE:MRK) Q1 2024 Earnings Call Transcript April 25, 2024 Merck & Co., Inc. beats...
Sutent Dosage: Form, Strengths, How to Take, and More
Healthline· 4 days agoSutent is a prescription drug used to treat certain types of cancer. Learn about the drug's dosages, form, strengths, how to take it, and more.
Exelixis (NASDAQ:EXEL) Earns “Outperform” Rating from William Blair
ETF DAILY NEWS· 1 day agoWilliam Blair reaffirmed their outperform rating on shares of Exelixis (NASDAQ:EXEL – Free Report) in a report published on Wednesday, RTT News reports. Barclays lowered Exelixis from an overweight ...
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives $24.64 Average Target Price from Analysts
ETF DAILY NEWS· 5 days agoShares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) have been given a consensus rating of “Buy” by the ten ratings firms that are currently covering the stock, Marketbeat ...